Cinnarizine

규격

298-57-7CAS 번호

206-064-8EC 번호

1-benzhydryl-4-[(E)-3-phenylprop-2-enyl]piperazineIUPAC 명칭

C26H28N2화학식

368.5 g/mol분자량

cinnarizine; 298-57-7; Stugeron; Dimitron; Folcodal; Labyrin; Midronal; Mitronal; Stutgeron; Stutgin; Glanil; Sepan; Aplactan; Cinazyn; Cinarizine; Cinnageron; Cinaperazine; Cinarizina; Aplexal; Cinnarizinum; Cinnipirine; Processine; Sedatromin; Spaderizine; Carecin; Cerebolan; Cinnacet; Corathiem; Denapol; Giganten; Hilactan; Ixertol; Katoseran; Siptazin; Artate; Eglen; Olamin; Votegol; Zepamol; 1-Cinnamyl-4-(diphenylmethyl)piperazine; 516 MD; R 516; R 1575; Stunarone; 1-Benzhydryl-4-cinnamylpiperazin; R-516; 1-(Diphenylmethyl)-4-(3-phenyl-2-propenyl)piperazine; R-1575; 3DI2E1X18L; DTXSID3022821; 516-MD; NSC-758400; 1-(diphenylmethyl)-4-(3-phenylprop-2-en-1-yl)piperazine; CHEBI:31403; 5-23-01-00233 (Beilstein Handbook Reference); 1-(di(phenyl)methyl)-4-(3-phenylprop-2-enyl)piperazine; 1-[di(phenyl)methyl]-4-(3-phenylprop-2-enyl)piperazine; cinnarizina; Stugeron Forte; Stugeron fte; cinnarizin von ct; Marzine r.f.; Cinnarizin-ratiopharm; Von Ct, Cinnarizin; Cinnarizin Ratiopharm; Mylan travel sickness; Cinnarizine L Tartrate; RefChem:577233; Dihydrochloride Cinnarizine; DTXCID50809707; N07CA02; MD516; R516; 206-064-8; Dimitronal; Toliman; Lazeta; 1-Benzhydryl-4-cinnamylpiperazine; Cerepar; 16699-20-0; 1-(diphenylmethyl)-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine; Piperazine, 1-(diphenylmethyl)-4-(3-phenyl-2-propenyl)-; 1-benzhydryl-4-[(E)-3-phenylprop-2-enyl]piperazine; (Z)-Cinnarizine; C26H28N2; 1-benzhydryl-4-[(E)-cinnamyl]piperazine; CHEMBL43064; 1-trans-Cinnamyl-4-diphenylmethylpiperazine; MLS000028498; Piperazine, 1-cinnamyl-4-(diphenylmethyl)-; 1-(diphenylmethyl)-4-(3-phenyl-2-propenyl)-piperazine; Libotasin; Senoger; SMR000058307; Cero-Aterin; MFCD00056037; PIPERAZINE, 1-(DIPHENYLMETHYL)-4-(3-PHENYL-2-PROPEN-1-YL)-; Cinarizina [INN-Spanish]; Cinnarizinum [INN-Latin]; DTXCID802821; 4-((2E)-3-phenylprop-2-enyl)-1-(diphenylmethyl)piperazine; Apotomin; Stonoron; Cinnarizine [USAN:INN:BAN:JAN]; SR-01000003093; EINECS 206-064-8; MD 516; BRN 0626121; UNII-3DI2E1X18L; Cinnarizine (JAN/USAN/INN); Cinnarizine?; Aplactan;; Mitronal;; Cinnarizine CRS; N-Benzhydryl-N'-cinnamylpiperazine; NCGC00015246-02; CAS-298-57-7; Cinnarizine, powder; Prestwick_115; Piperazine, (E)-; 1-(Diphenylmethyl)-4-(3-phenyl-2-propen-1-yl)piperazine; Cinnarizine (Standard); CINNARIZINE [MI]; Opera_ID_1776; Prestwick2_000278; Prestwick3_000278; CINNARIZINE [INN]; CINNARIZINE [JAN]; CINNARIZINE [USAN]; C 5270; CINNARIZINE [MART.]; Lopac0_000314; SCHEMBL44957; BSPBio_000156; CINNARIZINE [WHO-DD]; MLS001148649; MLS002207295; MLS002222167; BPBio1_000172; GTPL9072; orb1310183; cid_1547484; HY-B1090R; CINNARIZINE [EP IMPURITY]; DTXSID80859311; CHEBI:131176; CINNARIZINE [EP MONOGRAPH]; GLXC-06142; HMS1568H18; HMS2095H18; HMS2234B20; HMS3260P10; HMS3712H18; HMS3885F20; HMS5083E22; component of Emesazine (Salt/Mix); HY-B1090; MSK10646; Tox21_110109; Tox21_500314; BDBM50017657; EBC-26817; EBC-85024; NSC290687; NSC771642; SBB057016; STK216257; AKOS002134299; Stugeron|Dimitronal|Stutgin|Cinarizine; Tox21_110109_1; CCG-204409; CS-4656; FC20452; KS-5155; LP00314; NSC 758400; NSC-290687; NSC-771642; SDCCGSBI-0050302.P002; QTL1_000023; NCGC00018187-03; NCGC00018187-04; NCGC00018187-05; NCGC00018187-06; NCGC00018187-07; NCGC00018187-09; NCGC00018187-14; NCGC00021488-03; NCGC00021488-04; NCGC00021488-05; NCGC00260999-01; LS-15144; ST069378; EU-0100314; NS00006812; S4727; D01295; D89561; EN300-18169892; F814438; L001227; Q775073; 1-Benzhydryl-4-[3-phenyl-2-propenyl]piperazine #; doi:10.14272/DERZBLKQOCDDDZ-JLHYYAGUSA-N.1; SR-01000003093-2; SR-01000003093-6; BRD-K07220430-001-03-6; BRD-K07220430-001-18-4; BRD-K07220430-001-19-2; BRD-K74927006-001-01-2; (E)-1-(Diphenylmethyl)-4-(3-phenylprop-2-enyl)piperazine; Cinnarizine, European Pharmacopoeia (EP) Reference Standard; N90동의어